The Car T Cell Therapy For Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Car T Cell Therapy For Multiple Myeloma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Car T Cell Therapy For Multiple Myeloma Market.
Some of the key takeaways from the Car T Cell Therapy For Multiple Myeloma Pipeline Report:
- Companies across the globe are diligently working toward developing novel Car T Cell Therapy For Multiple Myeloma treatment therapies with a considerable amount of success over the years.
- Car T Cell Therapy For Multiple Myeloma companies working in the treatment market are Sana Biotechnology, MedTherapy, Caribou Biosciences, Allogene Therapeutics, Nexcella, Inc., Arcellx, Inc., Yake Biotechnology, Cartesian Therapeutics, IASO Biotherapeutics, CARsgen, Arcellx, Novartis, Bristol-Myers Squibb, Poseida Therapeutics, Juno Therapeutics, and others, are developing therapies for the Car T Cell Therapy For Multiple Myeloma treatment
- Emerging Car T Cell Therapy For Multiple Myeloma therapies in the different phases of clinical trials are- SC-255, MTB-003, CB-011, ALLO-715, NXC-201, CART-ddBCMA, BCMA CAR-T cells, Descartes 11, CT-103ANanjing, CT 053, CART-ddBCMA, PHE885, Orvacabtagene Autoleucel, Zevorcabtagene autoleucel (zevor-cel or CT053), P-BCMA-ALLO1, CC-95266, and others are expected to have a significant impact on the Car T Cell Therapy For Multiple Myeloma market in the coming years.
- In January 2023, CARsgen Therapeutics has revealed a partnership with Huadong Medicine to market zevorcabtagene autoleucel (zevor-cel), CT053, in mainland China. CT053, CARsgen’s fully human, autologous BCMA CAR T-cell product candidate, is specifically designed for the treatment of relapsed/refractory multiple myeloma (R/R MM).
- In October 2022, CARsgen Therapeutics Holdings Limited revealed that China’s National Medical Products Administration (NMPA) has approved the acceptance of the New Drug Application (NDA) for zevorcabtagene autoleucel (“zevor-cel,” R&D code: CT053). This therapy, a fully human, autologous BCMA CAR T-cell treatment, targets relapsed and/or refractory multiple myeloma (R/R MM).
Car T Cell Therapy For Multiple Myeloma Overview
The majority of individuals with multiple myeloma (MM), a malignant plasma cell condition, will never fully recover from the disease due to recurrent clonal evolution-induced novel mutations that give MM high-risk characteristics and resistance to conventional therapy. The treatment choices for multiple myeloma (MM) have changed dramatically over the last 20 years. Adoptive T cell therapy, in particular, has contributed to an exceptional response rate and clinical performance.
Get a Free Sample PDF Report to know more about Car T Cell Therapy For Multiple Myeloma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight
Emerging Car T Cell Therapy For Multiple Myeloma Drugs Under Different Phases of Clinical Development Include:
- SC-255: Sana Biotechnology
- MTB-003: MedTherapy
- CB-011: Caribou Biosciences
- ALLO-715: Allogene Therapeutics
- NXC-201: Nexcella, Inc.
- CART-ddBCMA: Arcellx, Inc.
- BCMA CAR-T cells: Yake Biotechnology
- Descartes 11: Cartesian Therapeutics
- CT-103ANanjing: IASO Biotherapeutics
- CT 053: CARsgen
- CART-ddBCMA: Arcellx
- PHE885: Novartis
- Orvacabtagene Autoleucel: Bristol-Myers Squibb
- Zevorcabtagene autoleucel (zevor-cel or CT053): CARsgen Therapeutics
- P-BCMA-ALLO1: Poseida Therapeutics
- CC-95266: Juno Therapeutics
Car T Cell Therapy For Multiple Myeloma Route of Administration
Car T Cell Therapy For Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
Car T Cell Therapy For Multiple Myeloma Molecule Type
Car T Cell Therapy For Multiple Myeloma Products have been categorized under various Molecule types, such as
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Car T Cell Therapy For Multiple Myeloma Pipeline Therapeutics Assessment
- Car T Cell Therapy For Multiple Myeloma Assessment by Product Type
- Car T Cell Therapy For Multiple Myeloma By Stage and Product Type
- Car T Cell Therapy For Multiple Myeloma Assessment by Route of Administration
- Car T Cell Therapy For Multiple Myeloma By Stage and Route of Administration
- Car T Cell Therapy For Multiple Myeloma Assessment by Molecule Type
- Car T Cell Therapy For Multiple Myeloma by Stage and Molecule Type
DelveInsight’s Car T Cell Therapy For Multiple Myeloma Report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Car T Cell Therapy For Multiple Myeloma product details are provided in the report. Download the Car T Cell Therapy For Multiple Myeloma pipeline report to learn more about the emerging Car T Cell Therapy For Multiple Myeloma therapies
Some of the key companies in the Car T Cell Therapy For Multiple Myeloma Therapeutics Market include:
Key companies developing therapies for Car T Cell Therapy For Multiple Myeloma are – Cartesian Therapeutics, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics, and others.
Car T Cell Therapy For Multiple Myeloma Pipeline Analysis:
The Car T Cell Therapy For Multiple Myeloma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Car T Cell Therapy For Multiple Myeloma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Car T Cell Therapy For Multiple Myeloma Treatment.
- Car T Cell Therapy For Multiple Myeloma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Car T Cell Therapy For Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Car T Cell Therapy For Multiple Myeloma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Car T Cell Therapy For Multiple Myeloma drugs and therapies
Car T Cell Therapy For Multiple Myeloma Pipeline Market Drivers
- Increasing prevalence of Multiple Myeloma, increase in technological advancement of CAR T-cell manufacturing in myeloma are some of the important factors that are fueling the Car T Cell Therapy For Multiple Myeloma Market.
Car T Cell Therapy For Multiple Myeloma Pipeline Market Barriers
- However, high cost associated with the treatment, poor persistence of CAR T cells and other factors are creating obstacles in the Car T Cell Therapy For Multiple Myeloma Market growth.
Scope of Car T Cell Therapy For Multiple Myeloma Pipeline Drug Insight
- Coverage: Global
- Key Car T Cell Therapy For Multiple Myeloma Companies: Sana Biotechnology, MedTherapy, Caribou Biosciences, Allogene Therapeutics, Nexcella, Inc., Arcellx, Inc., Yake Biotechnology, Cartesian Therapeutics, IASO Biotherapeutics, CARsgen, Arcellx, Novartis, Bristol-Myers Squibb, Poseida Therapeutics, Juno Therapeutics, and others
- Key Car T Cell Therapy For Multiple Myeloma Therapies: SC-255, MTB-003, CB-011, ALLO-715, NXC-201, CART-ddBCMA, BCMA CAR-T cells, Descartes 11, CT-103ANanjing, CT 053, CART-ddBCMA, PHE885, Orvacabtagene Autoleucel, Zevorcabtagene autoleucel (zevor-cel or CT053), P-BCMA-ALLO1, CC-95266, and others
- Car T Cell Therapy For Multiple Myeloma Therapeutic Assessment: Car T Cell Therapy For Multiple Myeloma current marketed and Car T Cell Therapy For Multiple Myeloma emerging therapies
- Car T Cell Therapy For Multiple Myeloma Market Dynamics: Car T Cell Therapy For Multiple Myeloma market drivers and Car T Cell Therapy For Multiple Myeloma market barriers
Request for Sample PDF Report for Car T Cell Therapy For Multiple Myeloma Pipeline Assessment and clinical trials
Table of Contents
1. Car T Cell Therapy For Multiple Myeloma Report Introduction
2. Car T Cell Therapy For Multiple Myeloma Executive Summary
3. Car T Cell Therapy For Multiple Myeloma Overview
4. Car T Cell Therapy For Multiple Myeloma- Analytical Perspective In-depth Commercial Assessment
5. Car T Cell Therapy For Multiple Myeloma Pipeline Therapeutics
6. Car T Cell Therapy For Multiple Myeloma Late Stage Products (Phase II/III)
7. Car T Cell Therapy For Multiple Myeloma Mid Stage Products (Phase II)
8. Car T Cell Therapy For Multiple Myeloma Early Stage Products (Phase I)
9. Car T Cell Therapy For Multiple Myeloma Preclinical Stage Products
10. Car T Cell Therapy For Multiple Myeloma Therapeutics Assessment
11. Car T Cell Therapy For Multiple Myeloma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Car T Cell Therapy For Multiple Myeloma Key Companies
14. Car T Cell Therapy For Multiple Myeloma Key Products
15. Car T Cell Therapy For Multiple Myeloma Unmet Needs
16 . Car T Cell Therapy For Multiple Myeloma Market Drivers and Barriers
17. Car T Cell Therapy For Multiple Myeloma Future Perspectives and Conclusion
18. Car T Cell Therapy For Multiple Myeloma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services